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experimental conditions our Cas9 nuclease is efficient at
cleaving the target sequence, and the TYMP cDNA is cor-
rectly inserted and expressed.
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UAM). Madrid, Spain. 2: Molecular Oncology Unit-CIEMAT
and Centro de Investigación Biomédica en Red de Cancer
(CIBERONC), Madrid, Spain. 3: Health Research Institute of
Aragón (IIS Aragón), Zaragoza, Spain. 4: Health Research
Institute of Aragón (IIS Aragón), Zaragoza, Spain; Centro de
Investigación Biomédica en Red de Enfermedades Hepáticas y
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Primary Hyperoxaluria Type 1 (PH1) is an inherited rare meta-
bolic liver disease caused by the deficiency in the alanine: glyoxylate
aminotransferase enzyme (AGXT), involved in the glyoxylate me-
tabolism. The only potentially curative treatment is organ trans-
plantation. Thus, the development of new therapeutic approaches for
the treatment of these patients appears as a priority. We propose the
combination of site-specific gene correction and direct cell repro-
gramming for the generation of autologous phenotypically healthy
induced hepatocytes (iHeps) from skin-derived fibroblast of PH1
patients. For the correction of AGXT mutations, we have designed
specific gene editing tools to address gene correction by two different
strategies, assisted by CRISPR/Cas9 system. Accurate specific point
mutation correction (c.853T-C) has been achieved by homology-
directed repair (HDR) with ssODN harbouring wild-type sequence.
In the second strategy, an enhanced version of AGXT cDNA has been
inserted near the transcription start codon of the endogenous gene,
constituting an almost universal correction strategy for PH1 muta-
tions. Direct reprogramming of fibroblasts has been conducted by
overexpression of hepatic transcription factors and in vitro culture in
defined media. In vitro characterization of healthy induced hepato-
cytes (iHeps) has demonstrated hepatic function of the repro-
grammed cells. PH1 patient fibroblasts and the gene edited
counterparts have also been reprogrammed to iHeps, showing similar
general hepatic characteristics as healthy iHeps. Restoration of the
glyoxylate metabolism in the gene edited and reprogrammed iHeps is
being demonstrated. The development of these advanced therapies
will be useful as alternative cellular source to replace endogenous
deficient hepatocytes with functional corrected cells.
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Fabry disease is caused by decrease or loss in the activity of a-
galactosidase (GLA), and its substrate globotriaosylceramide
(Gb-3) accumulates in cells throughout the body, resulting in
kidney injury and heart failure due to hypertrophy. Enzyme re-
placement therapy (ERT) has been used as a standard therapy,
but it is a significant financial burden and the regular adminis-
tration schedule is inconvenient for patients. In this study, we
examined whether GLA secreted from donor cells could be an
alternative to ERT. First, we established Gla-knockout (Gla-KO)
mice (C57BL/6 background) by CRISPR. Gla-KO mice ex-
hibited no Gla activity and accumulation of Gb-3, which is not
recognized in the previous reported Gla-KO mice. Next, syn-
geneic wild-type mouse embryonic fibroblasts were cultured
with a recombinant collagen peptide, called l-piece, on 96U-
bottom plate to produce cellular spheroid (hereafter referred to
as CellSaic), and transplanted under the renal capsule of Gla-KO
mouse. CellSaic protected central necrosis of cellular spheroid in
long-term culture. One month after transplantation, CellSaic was
clearly visible with vascular networks, and did not significantly
show TUNEL-positive cells. LysoGb-3 in liver of transplanted
mice significantly decreased depending on the number of Cell-
Saic (Control vs 20 CellSaic: p = 0.0002, vs 40 CellSaic:
p = 0.0004), suggesting that Gla secreted from CellSaic enters
into the circulation and degrades Gb-3 in the liver. These results
indicate the effectiveness of CellSaic to treat Fabry disease.
We’re planning ex vivo gene therapy in combination with
CellSaic technology to enable the strategy practicable with a
reasonable cell number.
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Objective: Due to the high proliferation rate along with affinity
to acquire hepatocyte functions, human adipose tissue-derived
stem cells (hASCs) have been considering as an important can-
didate for cell therapy of liver diseases. In addition, hepatocyte
nuclear factor a (HNF4a) has been redundantly reported as a key
transcription factor during early liver development. This factor is
essential for both hepatocyte differentiation and the maintenance
of hepatic functions. Therefore, the present study seeks whether
HNF4a can enhance hepatic differentiation of hASCs in the ab-
sence of any other stimulators.
Methods: Lentiviral transduction was applied to overexpress
HNF4a in hASCs for up to 21 days. Then hepatic functionality was
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